Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Targeting less common mutations in colorectal cancer

Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses targeting rare genetic alterations in patients with colorectal cancer. The Phase II MOUNTAINEER trial (NCT03043313) and the Phase II DESTINY-CRC01 trial (NCT03384940) assessed tucatinib with trastuzumab and trastuzumab deruxtecan respectively in patients with HER2-expressing metastatic colorectal cancer. More common mutations such as EFGR, RAS and BRAF are initially tested for first and next-generation sequencing (NGS) can take place upon relapse to detect rarer mutations such as NTRK and KRAS G12C. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.